JP2017514856A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514856A5
JP2017514856A5 JP2016566651A JP2016566651A JP2017514856A5 JP 2017514856 A5 JP2017514856 A5 JP 2017514856A5 JP 2016566651 A JP2016566651 A JP 2016566651A JP 2016566651 A JP2016566651 A JP 2016566651A JP 2017514856 A5 JP2017514856 A5 JP 2017514856A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
alkoxy
independently
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514856A (ja
JP6483156B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029409 external-priority patent/WO2015171722A1/en
Publication of JP2017514856A publication Critical patent/JP2017514856A/ja
Publication of JP2017514856A5 publication Critical patent/JP2017514856A5/ja
Application granted granted Critical
Publication of JP6483156B2 publication Critical patent/JP6483156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566651A 2014-05-07 2015-05-06 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ Active JP6483156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07
US61/989,651 2014-05-07
PCT/US2015/029409 WO2015171722A1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (3)

Publication Number Publication Date
JP2017514856A JP2017514856A (ja) 2017-06-08
JP2017514856A5 true JP2017514856A5 (enExample) 2018-04-19
JP6483156B2 JP6483156B2 (ja) 2019-03-13

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566651A Active JP6483156B2 (ja) 2014-05-07 2015-05-06 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ

Country Status (33)

Country Link
US (4) US9873679B2 (enExample)
EP (1) EP3140296B1 (enExample)
JP (1) JP6483156B2 (enExample)
KR (1) KR102336370B1 (enExample)
CN (1) CN106458976B (enExample)
AR (1) AR100328A1 (enExample)
AU (1) AU2015256120B2 (enExample)
BR (1) BR112016024936A2 (enExample)
CA (1) CA2948161C (enExample)
CL (1) CL2016002809A1 (enExample)
CY (1) CY1120340T1 (enExample)
DK (1) DK3140296T3 (enExample)
EA (1) EA033250B1 (enExample)
ES (1) ES2674531T3 (enExample)
HR (1) HRP20180641T1 (enExample)
HU (1) HUE039288T2 (enExample)
IL (1) IL248668B (enExample)
MA (1) MA39427B1 (enExample)
MX (1) MX378160B (enExample)
MY (1) MY181959A (enExample)
NZ (1) NZ727146A (enExample)
PE (1) PE20161363A1 (enExample)
PH (1) PH12016502034B1 (enExample)
PL (1) PL3140296T3 (enExample)
PT (1) PT3140296T (enExample)
RS (1) RS57170B1 (enExample)
SG (1) SG11201609170UA (enExample)
SI (1) SI3140296T1 (enExample)
SM (1) SMT201800342T1 (enExample)
TN (1) TN2016000444A1 (enExample)
TR (1) TR201809633T4 (enExample)
TW (1) TWI659951B (enExample)
WO (1) WO2015171722A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809633T4 (tr) * 2014-05-07 2018-07-23 Bristol Myers Squibb Co Diyabet gibi hastalıkların tedavisine yönelik pirolidin GPR40 modülatörleri.
KR20170002543A (ko) * 2014-05-07 2017-01-06 브리스톨-마이어스 스큅 컴퍼니 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
WO2018181847A1 (ja) * 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN107362365B (zh) * 2017-08-21 2020-01-07 武汉大风生物科技有限公司 Gpr31抑制剂在制药中的应用
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3217423A1 (en) 2021-06-16 2022-12-22 Jeffrey M. Schkeryantz Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
CN116283699B (zh) * 2023-03-02 2025-02-11 遵义医科大学 一种合成氟烷基取代的吡咯烷的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
CN102639495A (zh) * 2009-10-06 2012-08-15 百时美施贵宝公司 吡咯烷gpr40调节剂
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
WO2014022253A1 (en) 2012-08-01 2014-02-06 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
KR20150082618A (ko) 2012-11-16 2015-07-15 브리스톨-마이어스 스큅 컴퍼니 디히드로피라졸 gpr40 조절제
US9656963B2 (en) 2012-11-16 2017-05-23 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
HUE032401T2 (en) 2012-11-16 2017-09-28 Bristol Myers Squibb Co Dihydropyrazole GPR40 modulators
BR112015010649A2 (pt) * 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina
TR201809633T4 (tr) * 2014-05-07 2018-07-23 Bristol Myers Squibb Co Diyabet gibi hastalıkların tedavisine yönelik pirolidin GPR40 modülatörleri.
WO2015171757A1 (en) 2014-05-07 2015-11-12 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
WO2015169728A1 (en) 2014-05-07 2015-11-12 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome

Similar Documents

Publication Publication Date Title
JP7664947B2 (ja) Il-17の調節因子としてのイミダゾリダジン
JP7611278B2 (ja) 金属酵素阻害剤化合物
JP6130964B2 (ja) Apj受容体のトリアゾールアゴニスト
JP2018505203A5 (enExample)
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP2017508794A5 (enExample)
JP2016516043A5 (enExample)
JP2024514010A (ja) カルボキシ-ベンズイミダゾールglp-1r調節化合物
JP2016520128A5 (enExample)
JP2015500887A5 (enExample)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
JP2017508795A5 (enExample)
JP2017529389A5 (enExample)
JP2016526576A5 (enExample)
JP2017538722A5 (enExample)
JP2016525136A5 (enExample)
JP2017514865A5 (enExample)
JP2013518110A (ja) 疼痛および他の適応症の治療用の医薬組成物
WO2011074658A1 (ja) 新規抗血小板薬
WO2010122980A1 (ja) 新規甲状腺ホルモンβ受容体作動薬
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
JP2016513696A5 (enExample)
JP2021512114A5 (enExample)
CN112955448A (zh) 芳环或芳杂环类化合物及其制备方法和医药用途
JP2016513681A5 (enExample)